Omentin-1 vs DPDPE
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and DPDPE ([D-Pen2, D-Pen5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | DPDPE |
|---|---|---|
| Category | Diabetes & Metabolic | Pain Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | [D-Pen2, D-Pen5]-enkephalin |
| Molecular Weight | ~35 kDa | 645.79 Da |
| Half-Life | hours | 15-60 minutes in plasma |
| Amino Acids | 313 | 5 |
| Typical Dose | No approved human dose; research use only | 0.01-1 ug per animal |
| Route | IV|SC | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 800 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
DPDPE Benefits
- ✓delta-opioid selectivity
- ✓improved conformational stability
- ✓analgesic receptor mapping
- ✓useful in chronic pain models
Omentin-1 Dosing
not established|not established
DPDPE Dosing
Intrathecal 0.01-1 ug per animal|Intracerebroventricular 0.01-0.5 ug per animal|In vitro 0.1-20 nM
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
DPDPE Side Effects
- ⚠sedation
- ⚠nausea-like opioid effects
- ⚠tolerance with repeated dosing
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
DPDPE
DPDPE is widely cited in opioid pharmacology because it helped establish the functional role of delta-opioid receptors in pain control. Its constrained structure is also used to explore how peptide cyclization changes potency, stability, and tissue selectivity.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.